No votes yet

Myelodysplastic Syndromes

Sandra E. Kurtin
CJON 2012, 16(3), 5-7 DOI: 10.1188/12.CJON.S1.5-7

Myelodysplastic syndromes (MDS) represent a group of clonal myeloid malignancies with variability in clinical presentation and disease trajectory, as well as prognosis and treatment recommendations (Kurtin & Demakos, 2010). MDS is considered to be a rare disease that is most common in adults older than age 70. The disease is characterized by ineffective hematopoiesis, progressive bone marrow failure, and a variable risk of leukemic transformation thought to result from complex interactions between the malignant clone and the bone marrow microenvironment (Kurtin, 2011). This supplement is intended to provide the oncology clinician with an overview of MDS and provide tools for the clinical management and support of patients with MDS.


Bejar, R., Levine, R., & Ebert, B. L. (2011). Unraveling the molecular pathophysiology of myelodysplastic syndromes. <i>Journal of Clinical Oncology, 29</i>, 504-515. doi:10.1200/JCO.2010.31.1175

Cogle, C. R., Craig, B. M., Rollison, D. E., & List, A. F. (2011). Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: High number of uncaptured cases by cancer registries. <i>Blood, 117</i>, 7121-7125. doi:10.1182/blood-2011-02-337964

Dayyani, F., Conley, A. P., Strom, S. S., Stevenson, W., Cortes, J. E., Borthakur, G., … Garcia-Manero, G. (2010). Cause of death in patients with lower-risk myelodysplastic syndrome. <i>Cancer, 116</i>, 2174-2179. doi:10.1002/cncr.24984

Garcia-Manero, G. (2011). Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management. <i>American Journal of Hematology, 86</i>, 490-498. doi:10.1002/ajh.22047

Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., … Bennett, J. (1997). International scoring system for evaluating prognosis in myelodysplastic syndromes. <i>Blood, 89</i>, 2079-2088.

Greenberg, P., Tuechler, H., Schanz, J., Sole, F., Bennett, J. M., Garcia-Manero, G., … Haase, D. (2011). Revised International Prognostic Scoring System (IPSS-R), developed by the International Working Group for Prognosis in MDS (IWG-PM) [Abstract 14]. <i>Leukemia Research, 35</i>(Suppl. 1), S6.

Greenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., … Westervelt, P. (2011). Myelodysplastic syndromes. <i>Journal of the National Comprehensive Cancer Network, 9</i>, 30-56.

Komrokji, R. S., Sekeres, M. A., & List, A. F. (2011). Management of lower-risk myelodysplastic syndromes: The art and evidence. <i>Current Hematologic Malignancy Reports, 6</i>, 145-153. doi:10.1007/s11899-011-0086-x

Kurtin, S. (2011). Leukemia and myelodysplastic syndromes. In C. H. Yarbro, D. Wujcik, & B. H. Gobel (Eds.), <i>Cancer nursing: Principles and practice</i> (7th ed., pp. 1369-1398). Sudbury, MA: Jones and Bartlett.

Kurtin, S. E., Demakos, E., Hayden, J., & Boglione, C. (2012). Treatment of myelodysplastic syndromes: Practical tools and effective management. <i>Clinical Journal of Oncology Nursing, 16</i>(3, Suppl. 1), 23-35. doi:10.1188/12.CJON.S1.23-35

Kurtin, S. E., & Demakos, E. P. (2010). An update on the treatment of myelodysplastic syndromes [Online exclusive]. <i>Clinical Journal of Oncology Nursing, 14</i>, E29-E44. doi:10.1188/10.CJON.E24-E39

Kurtin, S. E., Paterson, P., Wintrich, S., Iraca, T., Hassan, A. A., Murray, D., & Hogan, S. (2012). Patient and family resources for living with myelodysplastic syndromes. <i>Clinical Journal of Oncology Nursing, 16</i>(3, Suppl. 1), 58-64. doi:10.1188/12.CJON.S1.58-64

Ma, X., Does, M., Raza, A., & Mayne, S. T. (2007). Myelodysplastic syndromes: Incidence and survival in the United States. <i>Cancer, 109</i>, 1536-1542. doi:10.1002/cncr.22570

Ridgeway, J. A., Fechter, L., Murray, C., & Borràs, N. (2012). Update on the science of myelodysplastic syndromes. <i>Clinical Journal of Oncology Nursing, 16</i>(3, Suppl. 1), 9-22. doi:10.1188/12.CJON.S1.9-22

Sekeres, M. A. (2011). Epidemiology, natural history, and practice patterns of patients with myelodysplastic syndromes in 2010. <i>Journal of the National Comprehensive Cancer Network, 9</i>, 57-63.

Shah, H., Kurtin, S. E., Arnold, L., Lindroos-Kolqvist, P., & Tinsley, S. (2012). Management of transfusion-related iron overload in patients with myelodysplastic syndromes. <i>Clinical Journal of Oncology Nursing, 16</i>(3, Suppl. 1), 37-46. doi:10.1188/12.CJON.S1.37-46

Steensma, D. P. (2011). The role of iron chelation therapy for patients with myelodysplastic syndromes. <i>Journal of the National Comprehensive Cancer Network, 9</i>, 65-75.

Thomas, M. L., Crisp, N., & Campbell, K. (2012). The importance of quality of life for patients living with myelodysplastic syndromes. <i>Clinical Journal of Oncology Nursing, 16</i>(3, Suppl. 1), 47-57. doi:10.1188/12.CJON.S1.47-57